| Literature DB >> 19625189 |
Mary T Didiuk1, David A Griffith, John W Benbow, Kevin K C Liu, Daniel P Walker, F Christopher Bi, Joel Morris, Angel Guzman-Perez, Hua Gao, Bruce M Bechle, Ryan M Kelley, Xiaojing Yang, Kenneth Dirico, Syed Ahmed, William Hungerford, Joseph DiBrinno, Michael P Zawistoski, Scott W Bagley, Jianke Li, Yuan Zeng, Stephanie Santucci, Robert Oliver, Matthew Corbett, Thanh Olson, Chiliu Chen, Mei Li, Vishwas M Paralkar, Keith A Riccardi, David R Healy, Amit S Kalgutkar, Tristan S Maurer, Hang T Nguyen, Kosea S Frederick.
Abstract
Synthesis and structure-activity relationship (SAR) studies on 5-trifluoromethylpyrido[4,3-d]pyrimidin-4(3H)-ones, a novel class of calcium receptor antagonists is described with particular emphasis on optimization of the pharmacokinetic/pharmacodynamic parameters required for a short duration of action compound. Orally-active compounds were identified which displayed the desired animal pharmacology (rapid and transient stimulation of parathyroid hormone) essential for bone anabolic effects.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19625189 DOI： 10.1016/j.bmcl.2009.07.004
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823